ROIV
Roivant Sciences LtdNASDAQ
Healthcare • Biotechnology
Factor tilt: Large-Cap Momentum
$38.88+6.17%
Close Nov 6, 2026
- Market cap
- $28.02B
- 1 month
- +13.7%
- 3 months
- +8.7%
- 1 year
- +92.2%
- 52-week range
- $20.10$41.81
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$0.45Quarter to Sep 30, 2026 · 3 analysts · revenue $4.11M · +0.4% in 30d
- Short interest
- 6.9% of float40.3M shares · settled Oct 15, 2026 · +2.6% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $7.53M
- Net income
- -$266.25M
- Free cash flow
- -$813.95M
- Book value
- $4.23B
- Total debt
- $107.15M
- P/E
- —
- Price / sales
- 3,720.6×
- Price / book
- 6.6×
- FCF yield
- -2.9%
- Net margin
- -3,534.9%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
Read more
Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
- Website
- roivant.com
- Headquarters
- London, United Kingdom
- Employees
- 721
- Listed
- Oct 1, 2021
- Fiscal year ends
- March
Company profile from EODHD, stored Oct 22, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 6, 2026 | $1.4M | -33.5% | 80.3% | -$366.0M | -$189.8M |
| Mar 2026filed May 20, 2026 | $2.5M | -66.7% | 87.3% | -$355.0M | $303.0M |
| Dec 2025filed Feb 6, 2026 | $2.0M | -77.8% | 65.0% | -$339.2M | -$265.9M |
| Sep 2025filed Nov 10, 2025 | $1.6M | -64.9% | 92.9% | -$306.2M | -$113.5M |
| Jun 2025filed Aug 11, 2025 | $2.2M | -51.5% | 92.9% | -$284.9M | -$223.4M |
| Mar 2025filed May 29, 2025 | $7.6M | -73.8% | 97.3% | -$285.0M | -$206.5M |
| Dec 2024filed Feb 10, 2025 | $9.0M | -42.1% | 97.1% | -$274.4M | $169.4M |
| Sep 2024filed Sep 30, 2024 | $4.5M | +22.7% | 94.8% | -$341.7M | -$230.2M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Mar 2026filed May 20, 2026 | $8.3M | -71.6% | 84.4% | -$1.3B | -$299.8M |
| Mar 2025filed May 29, 2025 | $29.1M | -11.2% | 96.9% | -$1.1B | -$172.0M |
| Mar 2024filed May 30, 2024 | $32.7M | +3.8% | 95.1% | -$824.9M | $4.3B |
| Mar 2023filed Jun 28, 2023 | $31.5M | -43.0% | 90.4% | -$809.0M | -$1.0B |
| Mar 2022filed Jun 28, 2022 | $55.3M | +132.3% | 83.8% | -$1.2B | -$845.3M |
| Mar 2021filed Mar 31, 2021 | $23.8M | -64.8% | 91.4% | -$1.1B | -$809.2M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched ROIV. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
40,302,998 shares short
+1,006,368 shares (+2.6%) vs Sep 30, 2026
6.9% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
39,296,630 shares short
+3,115,082 shares (+8.6%) vs Sep 15, 2026
6.8% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
36,181,548 shares short
+2,659,248 shares (+7.9%) vs Aug 31, 2026
6.8% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
33,522,300 shares short
+2,920,574 shares (+9.5%) vs Aug 14, 2026
6.3% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
30,601,726 shares short
-4,632,092 shares (-13.1%) vs Jul 31, 2026
5.8% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
35,233,818 shares short
-1,461,740 shares (-4%) vs Jul 15, 2026
6.6% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind ROIV’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if ROIV is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
77 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Oct 30, 2026
Smart-money 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 2 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
500 filers reported a long position in ROIV for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
53.1%
of the 556.8M shares 13-F filers reported
Moves vs Q1 2026
8 added2 trimmed
Net shares held
+3.9%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | FMR LLC | $2.9B · 81M shares | 81M | +3.9% |
| 2 | BlackRock, Inc. | $1.7B · 48.2M shares | 48.2M | +9% |
| 3 | MORGAN STANLEY | $1.5B · 42.6M shares | 42.6M | -17.8% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | $782.9M · 22.1M shares | 22.1M | +7% |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | $765.9M · 21.6M shares | 21.6M | +9.1% |
| 6 | GOLDMAN SACHS GROUP INC | $656.7M · 18.6M shares | 18.6M | +67% |
| 7 | STATE STREET CORP | $629.8M · 17.8M shares | 17.8M | +9.9% |
| 8 | UBS Group AG | $618.1M · 17.5M shares | 17.5M | -22.8% |
| 9 | FARALLON CAPITAL MANAGEMENT, L.L.C. | $506.4M · 14.3M shares | 14.3M | +47.9% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | $425.5M · 11.7M shares | 11.7M | +14.7% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of ROIV file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Nov 5, 2026 | FMR LLC13G · passive · amended | 11.8% |
| Oct 27, 2026 | BlackRock, Inc.13G · passive · amended | 8.2% |
| Aug 13, 2026 | MORGAN STANLEY13G · passive · amended | 5.7% |
| May 6, 2026 | Ramaswamy Vivek13G · passive · amended | 3.6%under 5% |
| Mar 27, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for ROIV
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.